Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 145-148

  MacKenzie, M J ^a   Rini, B I ^b   Elson, P ^b   Schwandt, A ^b   Wood, L ^b   Trinkhaus, M ^c   Bjarnason, G ^c   Knox, J ^d  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

MTOR; Renal cell carcinoma; Temsirolimus; TTP; VEGF

Indexed keywords

AMG 102; AXITINIB; BEVACIZUMAB; CEDIRANIB; CYCLOPHOSPHAMIDE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERLEUKIN 2; PANITUMUMAB; SORAFENIB; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; ASCITES; BRAIN METASTASIS; CANADA; CENTRAL NERVOUS SYSTEM INFECTION; COHORT ANALYSIS; COMPASSIONATE USE; CONFUSION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENUM PERFORATION; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; INTUSSUSCEPTION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; TERTIARY HEALTH CARE; UNITED STATES;

EID: 78650383149     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq320     Document Type: Article

References (12)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
3. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
4. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111.
5. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
6. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26(22): 3743-3748.
7. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27(27): 4462-4468.
8. Bojanapally PR, Graham S, Rustine et al. Temsirolimus for advanced renal cell carcinoma: compassionate versus commercial use. J Clin Oncol 2008; 26 (Suppl) (Abstr 16139).
9. Schmidinger M, Vogel UM, Lamm W et al. Temsirolimus in heavily pre-treated patients with metastatic renal cell carcinoma: preliminary results from the Austrian Compassionate Use Program. J Clin Oncol 2008; 26 (Suppl) (Abstr 16125).
10. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
11. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463.
12. Dutcher JP, de Souza P, Figlin R et al. Effect of temsirolimus versus interferon on survival of patients with advanced renal cell carcinoma of different tumor histologies. Proc Am Soc Clin Oncol Genitourinary Cancers Symposium 2008 (Abstr 384) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=54&abstractID=20205.